Company profile
ALLARITY THERAPEUTICS, INC.
NASDAQ:ALLRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| 2X-121 | phase2 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04796324 | phase2 | terminated | 2021-03-01 | 2024-12-01 | Allarity Therapeutics | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. |
| NCT03562832 | phase2 | completed | 2018-06-20 | 2024-04-01 | Allarity Therapeutics | Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP |
| NCT03878849 | phase2 | recruiting | 2019-04-15 | 2027-03-01 | Allarity Therapeutics | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer |
| NCT03643107 | phase2 | completed | 2018-10-17 | 2021-10-01 | Allarity Therapeutics | Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) |
| NCT01861496 | phase1_2 | completed | 2013-04-01 | 2021-10-01 | Allarity Therapeutics | Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours |
FDA applications (0)
No records yet.